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Long QT syndrome
siRNAWith a prevalence of 1/2500, long QT Syndrome (LQTS) is one
of the leading causes of sudden cardiac death in young and
otherwise healthy individuals. LQTS is a proarrhythmic disorder
hallmarked by prolongation of cardiac repolarization due to
underlying ion channelopathies. This translates to the typical
electrocardiographic (ECG) ﬁndings of prolonged QT interval,
notched or biphasic T waves, and T wave alternans, and puts
individuals at high risk of developing ventricular tachyarrhyth-
mias and sudden cardiac death. To date, there are 13 subtypes of
LQTS classiﬁed according to the 13 identiﬁed genetic defects, all
encoding subunits of cardiac ion channels (Kþ , Naþ , Ca2þ) or ion
channel regulatory proteins. Current treatment options for LQTS
including beta-blockers, left cardiac sympathetic denervation, and
implantable cardioverter-deﬁbrillators are largely palliative [1].
Each of these existing modalities is associated with limitations
such as adverse effects related to drug and surgical therapies and
the limited lifespan of implantable devices.
In the age of molecular genetics, a molecular diagnosis of the
underlying ion channel defect not only establishes the disease
state but paves the way for personalized medicine. Recently, Lu
et al. adopted the use of RNA interference technology to target
and rescue the channelopathy phenotype observed in LQTS type
2 due to KCNH2 mutation [2]. RNA interference therapy is based
on the concept derived from the natural cellular mechanism
where sequence-speciﬁc gene silencing can be achieved by crea-
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cellular genes via an endogenous post-transcriptional gene silen-
cing mechanism. This speciﬁc gene targeting approach is thus a
new and attractive treatment option for genetic diseases such as
LQTS which may avoid the disadvantages of conventional treat-
ment modalities.
Lu et al.’s study is based on the concept that LQTS type 2 is
associated with mutations in the human ether-a-go-go-related
gene, encoding for the alpha-subunit of the IKr channel. Such
mutations lead to defective proteins that may either cause a
dominant negative effect on wild-type subunits, happloinsufﬁ-
ciency, or defective trafﬁcking. Blockage of IKr efﬂux from cells
will lead to a delay in phase 3 rapid repolarization of the action
potential and hence prolongation of QT interval. They hypothe-
sized that by gene silencing of E637-hERG mutants (a dominant-
negative mutation where a lysine was substituted with glutamic
acid at position 637 in the pore-S6 loop transmembrane segment
of hERG), would lead to relief of IKr inhibition and restore K
þ
current that is essential for cardiac repolarization, thereby pre-
venting arrhythmias associated with IKr. They transfected plas-
mids containing wild-type or mutant hERG and siRNA in HEK293
cells which do not usually express the hERG protein, and then a
systematic screening method via Western blot analysis was used
to select the siRNA sequence with the highest knocking-down
efﬁciency against E637-hERG mutant. Subsequently they charac-
terized the cellular localization and electrophysiological proper-
ties of the hERG channel in order to determine the effect of siRNA
on the molecular and electrophysiological function of IKr.
For the validation of the rescuing effect of siRNA, a three-step
approach was used. This was ﬁrst done at a molecular level using
Western blot analysis of hERG protein expression. Next, theylsevier B.V. All rights reserved.
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in hERG mutants via patch clamp analysis. Several parameters
were quantiﬁed including the voltage dependence of activation of
the hERG channel, the steady-state inactivation kinetics, as well
as the time course of deactivation. It was shown that siRNA
treatment not only restored the maximal current and tail current
amplitude of cells to a level comparable with their wild-type
counterparts, they also reinstated the lost kinetic properties of the
dominant negative hERG mutation. siRNA transformed both the
activation and the steady-state inactivation curves of cells to
closer to that observed in the wild-type controls, while it caused a
reduction in the activation voltage to a level comparable to that of
cells with wild-type hERG. siRNA also slowed down the rapid
channel inactivation of mutants. The kinetics of recovery from
inactivation was found to be unaffected by the addition of siRNA
as shown by the unaffected deactivating tail currents. These
observations occurred only in the cells with the presence of
mutant hERG proteins, further validating the selectivity of the
action of the designed siRNA. Finally, the authors postulated the
mechanistic role of siRNA in the restoration of function of mutant
hERG channels by showing that siRNA not only caused lower
expression of the dominant negative mutant proteins (and
thereby reducing its suppressive effect on wild-type channels),
but it also prevented defective trafﬁcking of the channel protein.
Fractionation assay as well as confocal microscopy conﬁrmed that
siRNA treatment restored the mature hERG protein to the plasma
membrane, where it serves its function gating the rapidly activat-
ing delayed rectiﬁer potassium current.
This study opens the possibility of novel gene therapies for the
treatment of genetic cardiac disorders such as LQTS. The authors
showed elegantly how a well-designed siRNA targeting a single
genetic mutation was effective in restoration of the protein function
in cells carrying a missense mutation. Their work can easily be
expanded further to targeting other known mutations of the LQTS
such as gain-of-function mutations in SCN5A encoding for cardiac
sodium channels or G572R and A561V of hERG proteins which have
also been shown to result in trafﬁcking defective phenotypes and
suppression of IKr current.
However, arguably the main limitation of this study is that it was
conducted using HEK293 cells, and will thus need to be validated in
cardiomyocytes. While further work will be needed to show that
siRNA treatment rescues the defective IKr current without affecting
other ionic currents. To take the current study a step further would
be to design and construct a lentiviral-mediated system of siRNA
delivery in an animal model and to study the prevention of cardiac
arrhythmias and sudden cardiac death. Another potential limitation
to the use of RNA interference therapeutics as done by Lu et al. is the
mode of delivery of siRNA. Currently, there are twomain approaches
to introduce siRNA into cells [4]: (1) an RNA-based approach where
a preformed synthetic 21 bp siRNA effector is delivered via various
carriers to the target cells (as used by Lu et al. in this study; or (2) aDNA-based strategy in which the siRNA effectors were produced by
intracellular processing of longer RNA hairpin transcripts. The
advantage of using direct introduction of synthetic siRNAs is that
it allows room for enhancement of stability and efﬁcacy and
decreases unintended off-target effects via chemical modiﬁcations.
The disadvantage of the approach adopted by Lu et al. is that the
gene silencing effect of direct use of synthetic siRNA is short-lived,
albeit potent. Furthermore, due to the size and their negative charge,
siRNAs cannot readily cross cell membranes making delivery a
challenging task [5,6]. In contrast, promoter-expressed siRNA
sequences potentially allow for a single treatment to achieve lasting
effects of gene silencing. Finally, one must also critique the results of
RNA interference mediated target gene knockdowns with due
caution. This is because certain unwanted side effects have been
observed from the myriad of studies done on RNAi based therapies
in a wide range of diseases [7]. These include unintentional activa-
tion of Toll-like receptors and type 1 interferon responses, as well as
competitive interference of the endogenous RNA interference path-
way components. High level of exogenous siRNAs may sequester
molecules in the endogenous RNA interference processing machin-
ery, preventing their processing of cognate cellular microRNA.
The ability of RNA interference to control expression of disease-
associated genes makes siRNA-based intervention an exciting new
therapeutic modality for personalized medicine for genetic diseases,
such as LQTS. However, before taking a step further to translate
bench research ﬁndings to the bedside, one will need to tackle
several practical aspects including establishing a tissue-speciﬁc or
even cell-speciﬁc delivery system of siRNA and prevention of
unwanted side effects such as dysregulation of non-target genes.
There remains further work to be done to bring this powerful tool
from the laboratory into a clinical setting for LQTS, but the prospect
of RNA interference therapeutics is promising.Conﬂict of interest
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